| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales/Revenue | 350.13K | 510.36K |
| Revenue Growth % | - | 0.46% |
| Cost of Goods Sold | 196.69K | 355K |
| COGS % of Revenue | 0.56% | 0.7% |
| Gross Profit | 153.44K | 155.36K |
| Gross Margin % | 0.44% | 0.3% |
| Gross Profit Growth % | - | 0.01% |
| Operating Expenses | 163.29K | 1.62M |
| OpEx % of Revenue | 0.47% | 3.17% |
| Selling, General & Admin | 160.56K | 1.13M |
| SG&A % of Revenue | 0.46% | 2.21% |
| Research & Development | 0 | 491.35K |
| R&D % of Revenue | - | 0.96% |
| Other Operating Expenses | 2.73K | -493 |
| Operating Income | -9.85K | -1.46M |
| Operating Margin % | -0.03% | -2.86% |
| Operating Income Growth % | - | -147.46% |
| EBITDA | -7.39K | -1.36M |
| EBITDA Margin % | -0.02% | -2.66% |
| EBITDA Growth % | - | -182.53% |
| D&A (Non-Cash Add-back) | 2.45K | 104.73K |
| EBIT | 19.79K | -1.39M |
| Net Interest Income | -1.85K | 11.04K |
| Interest Income | 290 | 11.81K |
| Interest Expense | 2.14K | 772 |
| Other Income/Expense | 27.5K | 75.45K |
| Pretax Income | 17.65K | -1.39M |
| Pretax Margin % | 0.05% | -2.72% |
| Income Tax | 4.09K | 25.08K |
| Effective Tax Rate % | 0.77% | 1.02% |
| Net Income | 13.56K | -1.41M |
| Net Margin % | 0.04% | -2.77% |
| Net Income Growth % | - | -105.1% |
| Net Income (Continuing) | 13.56K | -1.41M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | 0.00 | 0.00 |
| EPS Growth % | - | - |
| EPS (Basic) | 0.00 | 0.00 |
| Diluted Shares Outstanding | 0 | 0 |
| Basic Shares Outstanding | 0 | 0 |
| Dividend Payout Ratio | - | - |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Total Current Assets | 271.72K | 3.47M |
| Cash & Short-Term Investments | 87.1K | 3.13M |
| Cash Only | 87.1K | 3.13M |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 98.43K | 262.8K |
| Days Sales Outstanding | 102.61 | 187.95 |
| Inventory | 69.4K | 37.34K |
| Days Inventory Outstanding | 128.8 | 38.39 |
| Other Current Assets | 0 | 0 |
| Total Non-Current Assets | 49.49K | 3.4M |
| Property, Plant & Equipment | 14.3K | 88.08K |
| Fixed Asset Turnover | 24.48x | 5.79x |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 2.68M |
| Long-Term Investments | 10.62K | 0 |
| Other Non-Current Assets | 0 | 628.23K |
| Total Assets | 321.21K | 6.86M |
| Asset Turnover | 1.09x | 0.07x |
| Asset Growth % | - | 20.37% |
| Total Current Liabilities | 298.22K | 263.06K |
| Accounts Payable | 17.98K | 26.74K |
| Days Payables Outstanding | 33.36 | 27.5 |
| Short-Term Debt | 34.32K | 290 |
| Deferred Revenue (Current) | 0 | 0 |
| Other Current Liabilities | 344 | 0 |
| Current Ratio | 0.91x | 13.18x |
| Quick Ratio | 0.68x | 13.04x |
| Cash Conversion Cycle | 198.05 | 198.84 |
| Total Non-Current Liabilities | 0 | 10.92K |
| Long-Term Debt | 0 | 0 |
| Capital Lease Obligations | 0 | 5.68K |
| Deferred Tax Liabilities | 0 | 1.46K |
| Other Non-Current Liabilities | 0 | 3.77K |
| Total Liabilities | 298.22K | 273.98K |
| Total Debt | 47.58K | 22.55K |
| Net Debt | -39.52K | -3.11M |
| Debt / Equity | 2.07x | 0.00x |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | -4.59x | -1893.69x |
| Total Equity | 22.99K | 6.59M |
| Equity Growth % | - | 285.61% |
| Book Value per Share | - | - |
| Total Shareholders' Equity | 22.99K | 6.59M |
| Common Stock | 105.2K | 144.18K |
| Retained Earnings | -515.48K | -1.93M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 47.21K | 45.07K |
| Minority Interest | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | -55.66K | -1.84M |
| Operating CF Margin % | -0.16% | -3.6% |
| Operating CF Growth % | - | -32% |
| Net Income | 13.56K | -1.41M |
| Depreciation & Amortization | 2.45K | 104.73K |
| Stock-Based Compensation | 0 | 0 |
| Deferred Taxes | 4.09K | 26.58K |
| Other Non-Cash Items | 50.94K | 11.24K |
| Working Capital Changes | -126.7K | -567.81K |
| Change in Receivables | -63.86K | -11.02K |
| Change in Inventory | -30.57K | 28.52K |
| Change in Payables | 5.39K | 10.2K |
| Cash from Investing | -290 | -2.9M |
| Capital Expenditures | -290 | -74.91K |
| CapEx % of Revenue | 0% | 0.15% |
| Acquisitions | - | - |
| Investments | - | - |
| Other Investing | 0 | -2.84M |
| Cash from Financing | 113.89K | 7.73M |
| Debt Issued (Net) | - | - |
| Equity Issued (Net) | - | - |
| Dividends Paid | 0 | 0 |
| Share Repurchases | - | - |
| Other Financing | 93.54K | -99.56K |
| Net Change in Cash | - | - |
| Free Cash Flow | -55.95K | -4.75M |
| FCF Margin % | -0.16% | -9.3% |
| FCF Growth % | - | -83.86% |
| FCF per Share | - | - |
| FCF Conversion (FCF/Net Income) | -4.10x | 1.30x |
| Interest Paid | 2.14K | 772 |
| Taxes Paid | 0 | 0 |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Equity (ROE) | 58.97% | -42.69% |
| Return on Invested Capital (ROIC) | - | -63.31% |
| Gross Margin | 43.82% | 30.44% |
| Net Margin | 3.87% | -276.58% |
| Debt / Equity | 2.07x | 0.00x |
| Interest Coverage | -4.59x | -1893.69x |
| FCF Conversion | -4.10x | 1.30x |
| Revenue Growth | - | 45.76% |
YD Bio Limited Warrants (YDESW) reported $0.5M in revenue for fiscal year 2024. This represents a 46% increase from $0.4M in 2023.
YD Bio Limited Warrants (YDESW) grew revenue by 45.8% over the past year. This is strong growth.
YD Bio Limited Warrants (YDESW) reported a net loss of $1.4M for fiscal year 2024.
YD Bio Limited Warrants (YDESW) has a return on equity (ROE) of -42.7%. Negative ROE indicates the company is unprofitable.
YD Bio Limited Warrants (YDESW) had negative free cash flow of $4.7M in fiscal year 2024, likely due to heavy capital investments.